Summary of Research: Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Summary of Research : Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis. / Humle, Karin; Klanger, Boris; Kolkhof, Peter; Rosas, Sylvia E.; Rossing, Peter; Wright, Eugene; Jefferson, Nichole.
I: Diabetes Therapy, Bind 15, Nr. 9, 2024, s. 1861-1864.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Summary of Research
T2 - Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis
AU - Humle, Karin
AU - Klanger, Boris
AU - Kolkhof, Peter
AU - Rosas, Sylvia E.
AU - Rossing, Peter
AU - Wright, Eugene
AU - Jefferson, Nichole
N1 - Publisher Copyright: © The Author(s) 2024.
PY - 2024
Y1 - 2024
N2 - People living with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at risk of CKD progression and kidney failure. This is a summary of the FIDELITY pooled analysis where two clinical trials (FIDELIO-DKD and FIGARO-DKD) were performed to investigate the safety and efficacy of finerenone in people with T2D and CKD. The data from these two studies were combined and analyzed and it was found that those who took finerenone on top of standard-of-care medicine had a 14% reduced risk of having a cardiovascular event and 23% reduced risk of having a kidney event versus those who took placebo. Those who took finerenone were also more likely to have high blood potassium, but this was mostly manageable. A graphical abstract and translations of all content (Chinese, Japanese, German, Spanish, Brazilian-Portuguese, French) are available for this article.
AB - People living with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at risk of CKD progression and kidney failure. This is a summary of the FIDELITY pooled analysis where two clinical trials (FIDELIO-DKD and FIGARO-DKD) were performed to investigate the safety and efficacy of finerenone in people with T2D and CKD. The data from these two studies were combined and analyzed and it was found that those who took finerenone on top of standard-of-care medicine had a 14% reduced risk of having a cardiovascular event and 23% reduced risk of having a kidney event versus those who took placebo. Those who took finerenone were also more likely to have high blood potassium, but this was mostly manageable. A graphical abstract and translations of all content (Chinese, Japanese, German, Spanish, Brazilian-Portuguese, French) are available for this article.
KW - Cardiovascular disease
KW - Chronic kidney disease
KW - Finerenone
KW - Type 2 diabetes
U2 - 10.1007/s13300-024-01591-w
DO - 10.1007/s13300-024-01591-w
M3 - Journal article
C2 - 39028367
AN - SCOPUS:85199098162
VL - 15
SP - 1861
EP - 1864
JO - Diabetes Therapy
JF - Diabetes Therapy
SN - 1869-6953
IS - 9
ER -
ID: 400740956